Genentech, a member of the Roche, announced that the FDA has approved Vabysmo for the treatment of macular edema following retinal vein occlusion, or RVO. RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration, or AMD, and diabetic macular edema, or DME. Together, the three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
- Roche announces collaboration with Ibex Medical Analytics, Amazon Web Services
- Immunovant price target raised to $57 from $28 at Piper Sandler
- Roivant (NASDAQ:ROIV) Gains after Roche’s $7.1 Billion Buy of Televant
- Roche to acquire Telavant from Roivant Sciences for $7.1B upfront
Questions or Comments about the article? Write to editor@tipranks.com